How Biokit is driving Immunoassay Development

In-Vitro-Diagnostics are playing a significant role in current healthcare systems and our partners must provide to practitioners and their patients with innovative, reliable, and high-quality immunoassays in a sustainable and efficient way.

In Biokit we work alongside our partners to expand their immunoassay portfolio by de-risking their novel developments and reducing time-to market. This is a shared objective for all the company as we work towards reducing project uncertainties since the beginning of the project with a dedicated team within our R&D Department. Biokit R&D Core Technologies team pursues the objective of de-risking the development of a new immunoassay since the first steps of new assay formulation.

Join us in the webinar De-Risking New Immunoassay Development to hear how Biokit is driving Immunoassay development with the objective of reducing the risk at the first stages of development and thus reducing time-to market. We show some examples with a practical case of an immunoassay to detect a hormone.